Yashoda Super Specialty Kaushambi
The Subject Expert Committee of Drugs Controller General of India (DCGI) on Wednesday recommended Serum Institute’s indigenously developed quadrivalent human papillomavirus (qHPV) vaccine for cervical cancer patients.
“An expert panel of India’s central drug authority on Wednesday recommended granting of market authorisation to Serum Institute of India (SII) indigenously-developed India’s first Quadrivalent Human Papillomavirus vaccine (qHPV) against cervical cancer”, said a source.
The vaccine has been recommended for cervical cancer patients those above 9 years to 26 years of age for both male and female.According to the source, an application has also been sent to the National Technical Advisory Group on Immunisation (NTAGI).
The NTAGI may take the final decision on the HPV vaccine in the next meeting scheduled to be held on June 29.
Patients with heart disease, specifically those with heart failure, are especially vulnerable to the impacts…
As the air pollution levels spike and reached alarming levels in many cities across the…
Highlighting that Antimicrobial Resistance is a global health threat, the Minister of State for health…
SFI Green Heartfulness Run was held on November 17, 2024 at Indirapuram starting from Habitat…
The Indian Council of Medical Research (ICMR) has inked agreements with multiple stakeholders for the…
Pharma major Akums Drugs and Pharmaceuticals has secured a patent for its Room Temperature Stable…